Top Page
Nanosonics Limited
(Sydney:NAN)
Nanosonics Limited (NAN) vs. iShares MSCI Australia ETF (EWA)
Nanosonics Limited Business Overview & Revenue Model
Nanosonics Limited Earnings Call Summary
Nanosonics Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 198.52M | 198.93M | 171.56M | 167.51M | 119.73M | 101.83M |
| Gross Profit | 155.25M | 155.66M | 133.99M | 125.66M | 86.15M | 74.91M |
| EBITDA | 26.04M | 31.82M | 21.72M | 29.50M | 7.86M | 15.75M |
| Net Income | 20.68M | 20.68M | 12.97M | 19.88M | 3.74M | 8.58M |
Balance Sheet | ||||||
| Total Assets | 272.48M | 272.48M | 237.34M | 226.07M | 193.24M | 164.57M |
| Cash, Cash Equivalents and Short-Term Investments | 161.29M | 161.29M | 129.55M | 112.16M | 94.51M | 96.03M |
| Total Debt | 7.69M | 7.69M | 9.30M | 10.72M | 11.71M | 2.49M |
| Total Liabilities | 62.57M | 62.57M | 55.14M | 62.22M | 54.55M | 29.01M |
| Stockholders Equity | 209.91M | 209.91M | 182.20M | 163.86M | 138.69M | 135.57M |
Cash Flow | ||||||
| Free Cash Flow | 35.26M | 35.26M | 20.27M | 19.74M | -271.00K | 5.93M |
| Operating Cash Flow | 43.98M | 43.98M | 22.78M | 23.31M | 6.70M | 7.32M |
| Investing Cash Flow | -8.71M | -8.71M | -2.36M | -3.54M | -6.90M | -1.38M |
| Financing Cash Flow | -3.30M | -3.30M | -3.01M | -2.71M | -1.97M | -1.03M |
Nanosonics Limited Technical Analysis
Nanosonics Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$1.26B | 60.79 | 10.32% | ― | 15.60% | 58.74% | |
72 Outperform | AU$114.71M | 9.43 | 12.37% | 3.70% | -0.74% | 16.65% | |
67 Neutral | AU$149.90M | 24.54 | 12.35% | ― | 39.98% | -30.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$104.47M | -7.78 | -31.98% | ― | 34.20% | -23.90% | |
49 Neutral | AU$263.95M | -159.38 | -2.01% | ― | 16.93% | 76.47% | |
47 Neutral | AU$107.54M | -24.06 | -4.28% | ― | 7.38% | 82.39% |
Nanosonics Limited Corporate Events
Nanosonics Limited issued a notification about a minor typographical correction in a previous announcement related to unquoted equity securities. The update clarified a discrepancy of 1,000 rights allocated to a key management personnel (KMP), reflecting an accurate allocation of 405,184 rights instead of 404,184. While the correction was minor, it demonstrates the company’s commitment to detail, transparency, and maintaining stakeholder trust.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.43 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited announced a change in Director Michael Kavanagh’s interest in securities, specifically acquiring 405,184 Performance Rights under the Nanosonics Equity Plan as part of the company’s long-term incentive (LTI) strategy for 2026. This update reflects the company’s commitment to aligning executive incentives with the long-term strategic and financial goals, indicating a focus on sustainable growth and value delivery for stakeholders.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.43 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced the issuance of over two million unquoted performance rights as part of its employee incentive scheme. This move, aimed at motivating and retaining talent, highlights the company’s focus on aligning employee interests with its growth and strategic goals, with potential long-term benefits for stakeholders and its market position in the infection prevention sector.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.43 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited announced a change in the director’s interest, specifically involving Mr. Michael Kavanagh. The change pertains to the issuance of 59,233 Service Rights under the Nanosonics Equity Plan, reflecting the company’s ongoing commitment to aligning executive interests with shareholder value. This adjustment in securities is part of the company’s broader strategy to incentivize and retain key personnel, which could have implications for its operational focus and stakeholder engagement.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.43 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has achieved significant regulatory milestones for its CORIS endoscope cleaning system, securing registrations in Australia, the EU, and the UK. These certifications enable the company to commence a Controlled Market Release in the UK, Ireland, and Australia starting January 2026, marking a crucial step in its commercialisation strategy and potentially strengthening its market position in infection prevention solutions.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.43 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced an update regarding its ongoing on-market buy-back program. As of December 9, 2025, the company has repurchased a total of 355,909 ordinary fully paid securities, with an additional 51,000 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.43 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced a change in the director’s interest, specifically regarding Mr. Michael Kavanagh’s holdings. The change involves the exercise of 66,380 performance rights under the Nanosonics Omnibus Equity Plan, resulting in an increase in indirect ordinary shares held by Mr. Kavanagh. This adjustment reflects the company’s ongoing commitment to aligning leadership interests with shareholder value, potentially impacting stakeholder perceptions positively.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.43 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced a daily update regarding its ongoing on-market buy-back program, with a total of 65,909 ordinary fully paid securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure, potentially enhancing shareholder value and signaling confidence in its financial health.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced an update on its ongoing on-market buy-back program, which involves the repurchase of its ordinary fully paid securities. As of the latest update, the company bought back 98,000 securities on the previous day, adding to a total of 192,000 securities repurchased before that. This buy-back initiative reflects the company’s strategic efforts to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced the application for quotation of 152,842 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of an employee incentive scheme, potentially enhancing employee engagement and aligning their interests with company performance, which could positively impact the company’s operational dynamics and market positioning.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced an update regarding its ongoing on-market buy-back program, with a total of 95,000 ordinary fully paid securities bought back on the previous day, adding to the 97,000 securities bought back before that. This buy-back initiative is part of the company’s efforts to manage its capital structure and potentially enhance shareholder value, reflecting a strategic move that may influence its market positioning and stakeholder interests.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced an on-market buy-back of its ordinary fully paid securities, as indicated by the ASX security code NAN. This strategic financial move is likely aimed at optimizing the company’s capital structure and could have implications for shareholder value and market perception.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced a daily on-market buy-back of its ordinary fully paid securities, as part of its capital management strategy. The buy-back will be conducted through Goldman Sachs, indicating a proactive approach to managing its share capital, which may positively influence investor confidence and market perception.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced an update regarding its ongoing on-market buy-back program, with a total of 74,835 ordinary fully paid securities bought back on the previous day, contributing to a cumulative total of 425,624 securities repurchased. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:NAN) stock is a Hold with a A$4.50 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced an update regarding its ongoing on-market buy-back program. As of November 26, 2025, the company has repurchased a total of 425,624 ordinary fully paid securities, including 72,199 securities bought back on the previous day. This buy-back initiative is part of Nanosonics’ strategy to optimize its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:NAN) stock is a Hold with a A$4.50 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced an update regarding its ongoing share buy-back program. The company reported that it bought back a total of 75,323 ordinary fully paid securities on the previous day, adding to the cumulative total of 74,874 securities bought back prior. This buy-back initiative is part of Nanosonics’ strategy to manage its capital structure effectively, potentially enhancing shareholder value and signaling confidence in the company’s financial health.
The most recent analyst rating on (AU:NAN) stock is a Hold with a A$4.50 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has appointed William Haydon as the Regional President for North America, effective December 1, 2025, following the retirement of Ken Shaw. Haydon’s extensive experience in the medical device and healthcare technology sectors, particularly in infection prevention and endoscope reprocessing, aligns with Nanosonics’ strategic priorities as it prepares to commercialize its CORIS® platform, marking a significant step in its growth strategy.
The most recent analyst rating on (AU:NAN) stock is a Sell with a A$4.10 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
UBS Group AG and its related bodies corporate have ceased to be substantial shareholders of Nanosonics Limited as of November 3, 2025. This change in shareholding could impact the company’s shareholder structure and influence its market perception, potentially affecting investor confidence and the company’s strategic decisions.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited held its 2025 Annual General Meeting where all proposed resolutions were successfully carried. The meeting also marked the departure of Dr. Lisa McIntyre from the Board, as previously announced. This outcome reflects strong shareholder support and continuity in the company’s strategic direction, potentially reinforcing its market position and stakeholder confidence.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced a $20 million on-market share buy-back program for FY26, reflecting its strong financial position and confidence in long-term growth. This initiative is part of the company’s capital management strategy, supported by its cash reserves and history of predictable cash flows, and aims to deliver long-term value to shareholders while maintaining a strong balance sheet and investing in future growth opportunities.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced the application for quotation of 189,870 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move, involving securities issued under an employee incentive scheme, is part of the company’s strategic efforts to enhance its market presence and operational capabilities.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced the application for the quotation of 53,069 ordinary fully paid securities on the ASX. These securities are issued under an employee incentive scheme, reflecting the company’s ongoing efforts to incentivize and retain talent, which may enhance its operational capabilities and market position.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced its 2025 Annual General Meeting (AGM), which will be held as a hybrid event, allowing shareholders to participate either in person or online. This approach aims to increase accessibility and engagement, enabling shareholders to ask questions and vote in real time, reflecting the company’s commitment to transparency and stakeholder involvement.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$4.90 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.